Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.

@article{Tew2010Phase1S,
  title={Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.},
  author={William P. Tew and Michael M. Gordon and John R. Murren and J. -M. Dupont and Sandra D Pezzulli and Carol A. Aghajanian and Paul J Sabbatini and David Mendelson and Lawrence Schwartz and Scott J Gettinger and Amanda Psyrri and Jesse Cedarbaum and David R. Spriggs},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2010},
  volume={16 1},
  pages={358-66}
}
PURPOSE To determine the maximum tolerated dose or maximal administered dose and pharmacokinetic and safety profiles of s.c. administered vascular endothelial growth factor Trap (aflibercept), a novel antiangiogenic agent. EXPERIMENTAL DESIGN In this open-label, dose-escalation study, patients with advanced solid tumors were treated with subcutaneous doses of aflibercept at seven dose levels. Patients received a single dose of aflibercept and then underwent safety and pharmacokinetic… CONTINUE READING